A Web-based Intervention Study to Reduce High-risk Sexual Behavior by Persons Living With HIV AIDS (PLWH)

HIV Infections Clinical Trial

Official title:

A Randomized Controlled Clinical Trial of an Internet-based Prevention Intervention to Reduce STI in High-risk HIV Infected MSM

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01198418
• Other study ID #: CCTG 592
• Status: Completed
• Phase: N/A
• Start date: July 9, 2010
• Est. completion date: November 9, 2017

Study information

• Verified date: May 2020
• Source: University of California, San Diego
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a CCTG sponsored trial in collaboration with UCSD-AVRC investigators to get more information about the methods that are used on the internet to provide information on how to reduce the risk of giving or getting infections that are often or usually passed from one person to another during sexual or intimate contact (sexually transmitted infection (STI)). STIs include chlamydia, gonorrhea and syphilis. The purpose of this study is to develop methods that will allow someone who is living with HIV an easy way that they can get information and learn of ways on their own that can decrease their chances of getting sexually transmitted infections and ways that they can reduce the chance that they may transmit HIV to others.

Description:

Design: CCTG 592 is a randomized, controlled study that will compare the efficacy of web-based intervention to reduce high-risk sexual behavior by persons living with HIV AIDS (PLWH).

Duration: 48 weeks

Sample Size: 200 subjects (100 per arm) that will be randomized

Study Population: HIV-1-infected men who have sex with men (MSM) at least 18 years of age who have a recent history of transmission risk behavior.

Stratification: Subjects will be stratified based upon their baseline antiretroviral use, whether they have a home computer and by site.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 181
• Est. completion date: November 9, 2017
• Est. primary completion date: October 18, 2017
• Accepts healthy volunteers: No
• Gender: Male
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• HIV-1 infection, as documented by any licensed screening antibody test, such as ELISA, and confirmed by a second antibody test, such as Western blot, or detectable plasma HIV-1 RNA at any time prior to study entry. If an ELISA or Western Blot are not available, HIV infection may be documented by two HIV RNA values > 2000 copies/mL, drawn at least 24 hours apart. The HIV RNA assays should have been run at a CLIA approved laboratory or equivalent.

• 18 years of age or older.

• Male.

• At least one of the following:

• An HIV negative or unknown status sexual partner in the past three months.

• A sexually transmitted disease in the past 1 year (other than HIV).

• More than 2 male partners in past year.

• Unprotected anal sex in past 3 month.

• Capable of signing written informed consent.

• Read and comprehend English

• Adequate computer skills for study.

Exclusion Criteria:

• Uncontrolled psychiatric condition.

• Drug or alcohol users with use that in the opinion of the investigator, would limit follow-up and adequate consent

Related Conditions & MeSH terms

• Communicable Diseases
• HIV Infections
• Infection
• Sexually Transmitted Diseases
• Sexually Transmitted Infections

Intervention

Behavioral:
• Experimental
Internet-based intervention that assesses transmission risk and provides prevention messages

Locations

Country	Name	City	State
United States	University of Southern California	Los Angeles	California
United States	University of California, San Diego	San Diego	California
United States	University of California, Los Angeles (Harbor)	Torrance	California

Sponsors (4)

Lead Sponsor	Collaborator
University of California, San Diego	California HIV/AIDS Research Program, University of California, Los Angeles, University of Southern California

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	STI incidence	To compare the composite STI incidence of syphilis or Chlamydia trachomatis (CT) or Neisseria gonorrhea (GC) at any mucosal site among sexually active HIV-infected men during 12 months participation in an Internet risk reduction intervention compared to those that receive a survey instrument alone.; To compare the incidence of nonspecific urethritis by urinalysis and testing for Mycoplasma genitalum and trichomonas sp. among sexually active HIV-infected men during 12 months participation in an Internet risk reduction intervention compared to those that receive a survey instrument alone.	Baseline and follow-up visits every 3 months
Secondary	Evaluate risk factors of STIs	Compare:a)self reported levels of unsafe sex among HIV-infected men b)intention to start ARV among HIV-infected men not currently on ARV will increase during 12 mos. participation in an internet risk reduction intervention compared to survey instrument alone; Compare self-reported among HIV-infected men during 12 mos. participation as measured by those reporting 100% disclosure in an internet risk reduction intervention compared to survey instrument alone; Collect genital tract secretions of semen for future study	Baseline, follow-up visits every 3 months

External Links

•   (organization's website)